Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06253130 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Eikon Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 156
- Enrollment target
- 20
- Study locations
NCT06253130: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Eikon Therapeutics.
NCT06253130 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 156 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06253130, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Eikon Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 156 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.
Primary Outcome
Number of subjects reporting adverse events or serious adverse events which include any abnormal clinical events, laboratory assessments outside of normal clinical range, abnormal vital signs observed, and any abnormal ECG parameters
Conditions Studied
Interventions
- DRUG IMP1734
Study Locations (20)
California
- Hoag Health Center Irvine - Irvine
- University California Irvine - Irvine
- Sharp Memorial Hospital - San Diego
- University of California San Francisco (UCSF) - San Francisco
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
- Karmanos Cancer Institute - Detroit
- Henry Ford Health - Detroit
Florida
- Advent Health Research Institute - Celebration
- Sylvester Comprehensive Cancer Center - Miami
Arizona
- The University of Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas Winthrop P. Rockefeller Cancer Institute - Little Rock
Colorado
- Sarah Cannon Research Institute Health One - Denver
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
Minnesota
- University of Minnesota-Clinical Research Unit - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2023-12-11 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
What NCT06253130 shows while recruiting
NCT06253130 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IMP1734 is the first listed.
NCT06253130 names 20 study sites across 14 states, led by California, Michigan, Florida.
Frequently Asked Questions
What is clinical trial NCT06253130 about?
NCT06253130 is a clinical study titled "A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors". This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.
What is the current status of trial NCT06253130?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2023-12-11. Estimated completion is 2027-12-01.
What conditions does trial NCT06253130 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06253130?
The interventions under investigation include: IMP1734 (DRUG).
Who is sponsoring clinical trial NCT06253130?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06253130 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06253130's enrollment target sits among peer trials
156 82nd of 189 higher than 108 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI